

cIAP2 (BIRC3) Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP6124a

Specification

cIAP2 (BIRC3) Antibody (N-term) - Product Information

Application	WB, IHC-P,E
Primary Accession	Q13489
Other Accession	NP_892007
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit Ig
Antigen Region	101-131

cIAP2 (BIRC3) Antibody (N-term) - Additional Information

Gene ID 330

Other Names

Baculoviral IAP repeat-containing protein 3, 632-, Apoptosis inhibitor 2, API2, C-IAP2, IAP homolog C, Inhibitor of apoptosis protein 1, IAP-1, hIAP-1, hIAP1, RING finger protein 49, TNFR2-TRAF-signaling complex protein 1, BIRC3, API2, IAP1, MIHC, RNF49

Target/Specificity

This cIAP2 (BIRC3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 101-131 amino acids from the N-terminal region of human cIAP2 (BIRC3).

Dilution

WB~~1:1000


IHC-P~~1:10~50

Format


Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw



BIRC3 Antibody (S116) (Cat. #AP6124a) western blot analysis in A549 cell line lysates (35ug/lane). This demonstrates the BIRC3 antibody detected the BIRC3 protein (arrow).



cIAP2 (BIRC3) antibody (N-term) (Cat. #AP6124a) immunohistochemistry analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of cIAP2 (BIRC3) antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.

cycles.

Precautions

clAP2 (BIRC3) Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

clAP2 (BIRC3) Antibody (N-term) - Protein Information

Name BIRC3

Synonyms API2, MIHC, RNF49

Function

Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non- canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8.

Cellular Location

Cytoplasm. Nucleus

Tissue Location

Highly expressed in fetal lung, and kidney. In the adult, expression is mainly seen in lymphoid tissues, including spleen, thymus and peripheral blood lymphocytes

clAP2 (BIRC3) Antibody (N-term) - Background

BIRC3 is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2, probably by interfering with activation of ICE-like proteases. The encoded protein inhibits apoptosis induced by serum deprivation but does not affect apoptosis resulting from exposure to menadione, a potent inducer of free radicals. The amino acid sequence predicts three baculovirus IAP repeat domains and a ring finger domain.

clAP2 (BIRC3) Antibody (N-term) - References

Wang, Q., et al., J. Biol. Chem. 278(51):51091-51099 (2003).
Suguro-Katayama, M., et al., Leukemia 17(12):2508-2512 (2003).
Jonsson, G., et al., Anticancer Res. 23(4):3311-3316 (2003).
Yang, Q.H., et al., Genes Dev. 17(12):1487-1496 (2003).
Dai, Z., et al., Hum. Mol. Genet. 12(7):791-801 (2003).

**clAP2 (BIRC3) Antibody (N-term) -
Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

clAP2 (BIRC3) Antibody (N-term) - Citations

- [Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer.](#)
- [Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation.](#)